Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/Gastroenterology.2.023
Updates in the Treatment of Superficial Gastric Neoplasms by Endoscopic Submucosal Dissection
- 1Faculty of Medicine “Alberto Hurtado”, Cayetano Heredia Peruvian University, Digestive Endoscopy Unit of the San Pablo Clinic, Surco, Lima, Peru; Member of the Gastroenterology Society of Peru
- 2Endoscopy Unit, Alfa Institute of Gastroenterology, Federal University of Minas Gerais, Mater Dei Contorno Hospital, Belo Horizonte, Minas Gerais, Brazil
Vitor Arantes, email@example.com
Received Date: December 09, 2020
Accepted Date: January 25, 2021
Aliaga-Ramos J, Arantes V. Updates in the Treatment of Superficial Gastric Neoplasms by Endoscopic Submucosal Dissection. Arch Gastroenterol Res. 2021; 2(1): 26-30.
Copyright: © 021 Aliaga-Ramos J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Neoplasms; Endoscopy; Cancer; Virtual chromoendoscopy, Endoscopic,
Breast cancer is the second most common cancer worldwide, affecting nearly one in eight women. Accurate cancer staging is essential for determining the patient’s prognosis and for choosing the appropriate treatment.
Gastric cancer (GC), also known as stomach cancer, is a worldwide health problem. Anatomically, it can occur from the gastroesophageal junction to distal portions of the stomach. Considering both sexes, worldwide, it is the 5th most common neoplasm (5.7%) and the 3rd cause of mortality among malignancies, leading to approximately 782,000 deaths in 2018. The incidence varies geographically but 50% of new cases are diagnosed in developed countries. High incidence is observed in Asia, Latin America, and in the central and eastern parts of Europe. There are several ways to classify GC, but the most used is Lauren’s Classification, which proposes two main histological groups: intestinal and diffuse. This classification is important because there are marked etiological, pathological, and epidemiological differences between the subgroups, guiding the clinical approach for each patient.
Liver biopsy continues to be the gold-standard with regards to diagnosis and staging of the majority of liver diseases. Serologic markers certainly have helped in diagnosing various autoimmune and viral-related liver diseases. Furthermore, laboratory testing and imaging studies such as liver elastography have allowed us to non-invasively assess fibrosis. Unfortunately, there are shortcomings with these forms of testing. False positives or laboratory errors will lead to misleading diagnoses. Situations can also arise during which there are diagnostic dilemmas, such as an obese patient with positive autoimmune serology and elevated liver chemistries.
Gastric cancer is one of the neoplasms with the highest degree of mortality worldwide, responsible for more than 780,000 deaths in 2018 and whose incidence has been increasing over the last few years, mainly in Asian and Latin American countries. The technological imaging advances in digestive endoscopy such as virtual chromoendoscopy and magnification associated with a systematic and comprehensive endoscopic examination of the entire gastric mucosa by a trained operator have optimized the early detection of pre-malignant and malignant lesions, which have favoured the high rate of curability through the use of endoscopic resection techniques such as endoscopic submucosal dissection (ESD).
In this study, the safety and efficacy of liver biopsies performed by endoscopic ultrasound (EUS-LB) were compared with those performed via the traditional percutaneous route at our Medical Center between January 2018 and August 2019.